Sensus Healthcare, Inc.

Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a medical device company focused on non-invasive radiation therapy for dermatological conditions. Founded in 2011, it developed the SRT-100 system, which delivers superficial radiotherapy to treat basal cell carcinoma, squamous cell carcinoma, and keloids. The company operates from Boca Raton, Florida, per its public disclosures. Its strategy centers on commercializing the SRT-100 platform across US dermatology clinics and international markets, including China and Latin America. Sensus generates revenue through device sales, service contracts, and consumables. The company has not disclosed direct investments in other asset classes or portfolio companies beyond its own operations. As of its latest proxy filing, Sensus has fewer than 100 employees and is managed by CEO Joe Sardano. The company maintains FDA clearance for its devices and has secured regulatory approvals in Japan and the European Union. No philanthropic foundation or operating company has been publicly associated with Sensus outside its corporate structure. Sensus is a publicly traded corporation, not a family office or asset manager. Its distinctive structural feature is its focused product line—superficial radiotherapy—which occupies a narrow niche between surgery and other radiation modalities. The company has no known direct investment in other funds or co-investment platforms.